



**Universiteit  
Leiden**  
The Netherlands

**Response to: 'Correspondence on 'Historically controlled comparison of glucocorticoids with or without tocilizumab versus supportive care only in patients with COVID-19-associated cytokine storm syndrome: results of the CHIC study'' by Calvo-Aranda et al**

Ramiro, S.; Mostard, R.; Landewe, R.B.M.

**Citation**

Ramiro, S., Mostard, R., & Landewe, R. B. M. (2023). Response to: 'Correspondence on 'Historically controlled comparison of glucocorticoids with or without tocilizumab versus supportive care only in patients with COVID-19-associated cytokine storm syndrome: results of the CHIC study'' by Calvo-Aranda et al, 82(2).  
doi:10.1136/annrheumdis-2020-219534

Version: Publisher's Version

License: [Creative Commons CC BY-NC 4.0 license](#)

Downloaded from:

**Note:** To cite this publication please use the final published version (if applicable).

## Response to: 'Correspondence on 'Historically controlled comparison of glucocorticoids with or without tocilizumab versus supportive care only in patients with COVID-19- associated cytokine storm syndrome: results of the CHIC study' by Calvo-Aranda *et al*

We read with interest the letter from Calvo-Aranda *et al*<sup>1</sup> on our COVID high-intensity immunosuppression in cytokine storm syndrome study.<sup>2</sup> In our study, we have used in patients with COVID-19 associated cytokine storm syndrome (CSS) an immunosuppressive strategy consisting of glucocorticoids as first line, followed, by tocilizumab in case of insufficient response. Calvo-Aranda *et al* show us the results of their positive experience with a 3 days course of anakinra treatment (100 mg/day) in a series of nine patients with moderate-to-severe COVID-19, refractory to standard-of-care treatment.<sup>1</sup> Six out of nine patients achieved the composite endpoint that included radiological, clinical and analytical improvement within 72 hours. No radiological worsening was recorded in the remaining three patients.

The experience with anakinra reported by Calvo-Aranda is encouraging. We agree with the authors that anakinra may be an alternative option for the management of patients with COVID-19 associated CSS. Preliminary data on the effects of anakinra in this patient population have been published previously and cited in our manuscript.<sup>3,4</sup> We acknowledge that several immunosuppressive compounds, such as tumour necrosis factor alpha inhibitors and interleukin-1 receptor antagonists, may have similar effects.<sup>2</sup> We believe the international community is reaching consensus about the role of immunosuppression in the minority of patients with severe, life-threatening COVID-19. What remains to be investigated is the best immunosuppressive treatment strategy. One may think about individual agents, such as the ones mentioned, or switch between agents (eg, in case of insufficient response to the first), step-up therapy (eg, starting with one and adding another in case of insufficient response) or combination therapy (eg, combine drugs with different mechanisms of action). We are looking forward to well-conducted studies addressing this unmet need and comparing treatment interventions or strategies so that we can optimise the treatment of our patients.

Sofia Ramiro <sup>1,2</sup> Rémy Mostard,<sup>3</sup> Robert BM Landewé <sup>1,4</sup>

<sup>1</sup>Rheumatology, Zuyderland Medical Center, Heerlen, Limbug, The Netherlands

<sup>2</sup>Rheumatology, Leiden University Medical Center, Leiden, The Netherlands

<sup>3</sup>Department of Pulmonology, Zuyderland Medical Center, Heerlen, The Netherlands

<sup>4</sup>Amsterdam Rheumatology Center, AMC, Amsterdam, The Netherlands

**Correspondence to** Dr Sofia Ramiro, Rheumatology, Leiden University Medical Center, Leiden 2333GA, The Netherlands; sofiamramiro@gmail.com

**Correction notice** This article has been corrected since it published Online First. The provenance and peer review statement has been included.

**Handling editor** Josef S Smolen

**Contributors** SR drafted the response. All authors reviewed and approved the final response.

**Funding** The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

**Competing interests** None declared.

**Patient and public involvement** Patients and/or the public were not involved in the design, or conduct, or reporting, or dissemination plans of this research.

**Patient consent for publication** Not required.

**Provenance and peer review** Commissioned; internally peer reviewed.

This article is made freely available for personal use in accordance with BMJ's website terms and conditions for the duration of the covid-19 pandemic or until otherwise determined by BMJ. You may download and print the article for any lawful, non-commercial purpose (including text and data mining) provided that all copyright notices and trade marks are retained.

© Author(s) (or their employer(s)) 2023. No commercial re-use. See rights and permissions. Published by BMJ.



**To cite** Ramiro S, Mostard R, Landewé RBM. *Ann Rheum Dis* 2023;**82**:e35.

Received 2 December 2020

Accepted 4 December 2020

Published Online First 14 December 2020



► <http://dx.doi.org/10.1136/annrheumdis-2020-219479>

*Ann Rheum Dis* 2023;**82**:e35. doi:10.1136/annrheumdis-2020-219534

### ORCID iDs

Sofia Ramiro <http://orcid.org/0000-0002-8899-9087>

Robert BM Landewé <http://orcid.org/0000-0002-0577-6620>

### REFERENCES

- Calvo-Aranda E, Cañamares-Orbis I, Novella-Navarro M, *et al*. Correspondence on "Historically controlled comparison of glucocorticoids with or without tocilizumab versus supportive care only in patients with COVID-19- associated cytokine storm syndrome: results of the CHIC study". *Ann Rheum Dis* 2023;**82**:e34.
- Ramiro S, Mostard RLM, Magro-Checa C, *et al*. Historically controlled comparison of glucocorticoids with or without tocilizumab versus supportive care only in patients with COVID-19-associated cytokine storm syndrome: results of the CHIC study. *Ann Rheum Dis* 2020;**79**:1143–51.
- Cavalli G, De Luca G, Campochiaro C, *et al*. Interleukin-1 blockade with high-dose anakinra in patients with COVID-19, acute respiratory distress syndrome, and hyperinflammation: a retrospective cohort study. *Lancet Rheumatol* 2020;**2**:e325–31.
- Huet T, Beaussier H, Voisin O, *et al*. Anakinra for severe forms of COVID-19: a cohort study. *Lancet Rheumatol* 2020;**2**:e393–400.